Apexigen, Inc. logo

Apexigen, Inc.

Apexigen (spun-out of Epitomics, Inc.) is a biopharma company, developing monoclonal antibodies as a therapeutics for the treatment of cancer and inflammatory diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.apexigen.com
Founded2010
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
75 Shoreway Road, Suite C, CA 94070
San Carlos
United States
Email
Contact Number
+1 650-931-6236

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/apexigen” connections=”true” suffix=””]

Apexigen proprietary Mutation Lineage Guided humanization technology, utilizes the information derived from the rabbit antibody sequences which are much diverse compare to human or mouse and humanize the entire antibody to achieve a very high degree of humanization. The results are antibodies that retain full activity, offering key benefits compared to other humanization technologies.

In Dec 2010, Centocor Research & Development, Inc entered into a collaboration agreement to utilize Apexigens proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs.

Key partners include 3SBio, Inc., Centocor Research and Development, Inc., Gansu Duyiwei Biotechnology Ltd., Jiangsu T-mab Biotechnology, Ltd., Simcere Pharmaceutical Group.

In Aug. 2013, Apexigen secured $20 Mn USD in Series A1 financing led by Amkey Ventures LLC, WSR Capital, China Development Industrial Bank, Themes Investment Partners, and Sycamore Ventures.